ArticleNature2025
Small-molecule inhibition of SARS-CoV-2 NSP14 RNA cap methyltransferase.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Towards broader-spectrum direct-acting antivirals against RNA viruses.Nature reviews. Microbiology · 2026Review
- Structural and Mechanistic Perspectives on SARS-CoV-2 Nonstructural Protein 14-Mediated Cap Formation and Drug Discovery.Microorganisms · 2026Review
- Coronavirus NSP14 drives internal m7G modification to rewire host splicing and promote viral replication.Nucleic acids research · 2026Article
- ARF-like GTPase 8B orchestrates lipophagy and exocytosis to drive single-stranded RNA virus replication.Journal of translational medicine · 2026Article
- Structural dynamics of the π-stacking network governing cofactor-substrate cooperativity of SbSOMT methyltransferase.Communications chemistry · 2026Article
- Targeting SARS-CoV-2 Non-Structural Proteins: A Blueprint for Next-Generation Small-Molecule Coronavirus Antivirals.Pharmaceutics · 2026Review
- Extending the Targets for Coronavirus Antivirals Beyond That of Approved Drugs: Insights From Preclinical Research.Microbial biotechnology · 2026Review
- Inhibiting the interaction between the mitochondrial receptor Tom70 and SARS CoV 2 Orf9b with small molecules.bioRxiv : the preprint server for biology · 2026Article
- Dual antiviral and anti-inflammatory effects of BAY 11-7082 in SARS-CoV-2 infection via inhibition of the canonical NF-κB signaling pathway.Scientific reports · 2026Article
- Next-generation inhibitors of SARS-CoV-2 MNature communications · 2026Article
- Update of the Methyltransferase Gene Family: Classification, Evolution and Biological Functions.Human genomics · 2026Review
- Fragment-Based Development of NSP14 Exonuclease Inhibitors Confounded by Batch-to-Batch Variability.ACS chemical biology · 2026Article
- Article
- Molecular Aspects of Viral Pathogenesis in Emerging SARS-CoV-2 Variants: Evolving Mechanisms of Infection and Host Response.International journal of molecular sciences · 2026Review
- Crystallographic characterisation and development of bi-substrate inhibitors of coronavirus nsp14 methyltransferase.RSC medicinal chemistry · 2026Article
- Larval Metabolic and Physiological Mechanisms Underlying Resistance to Chinese Sacbrood Virus inInsects · 2025Article
- Structural and catalytic diversity of coronavirus proofreading exoribonuclease.Nature communications · 2025Article
- A SARS-CoV-2 MNature communications · 2025Article
- SARS-CoV-2 NSP14 inhibitor exhibits potent antiviral activity and reverses NSP14-driven host modulation.Nature communications · 2025Article
- Advances in Methods for Accurate Prediction of RNA-Small Molecule Binding Sites: From Isolated to AI-Integrated Strategies.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Cindy MeyerLaboratory for RNA Molecular Biology, The Rockefeller University, New York, NY, USA.
Aitor GarziaLaboratory for RNA Molecular Biology, The Rockefeller University, New York, NY, USA.ORCID 0000-0002-6270-1369
Michael W MillerSanders Tri-Institutional Therapeutics Discovery Institute, The Rockefeller University, New York, NY, USA.
David J HugginsSanders Tri-Institutional Therapeutics Discovery Institute, The Rockefeller University, New York, NY, USA.
Robert W MyersSanders Tri-Institutional Therapeutics Discovery Institute, The Rockefeller University, New York, NY, USA.
Hans-Heinrich HoffmannLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.ORCID 0000-0003-0554-0244
Alison W AshbrookLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.ORCID 0000-0003-1114-1426
Syeda Y JannathLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
Nigel LivertonSanders Tri-Institutional Therapeutics Discovery Institute, The Rockefeller University, New York, NY, USA.
Stacia KargmanSanders Tri-Institutional Therapeutics Discovery Institute, The Rockefeller University, New York, NY, USA.
Matthew ZimmermanCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.
Andrew M NelsonCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.
Vijeta SharmaCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.
Enriko DolgovCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.
Julianna CangialosiCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.
Suyapa Penalva-LopezCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.
Nadine AlvarezCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.
Ching-Wen ChangLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
Neelam OswalCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.
Irene GonzalezCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.ORCID 0000-0003-4821-4852
Risha RasheedCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.
Kira GoldgirshCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.
Jada A DavisLaboratory for RNA Molecular Biology, The Rockefeller University, New York, NY, USA.
Lavoisier Ramos-EspirituFisher Drug Discovery Resource Center, The Rockefeller University, New York, NY, USA.
Miriam-Rose MenezesFisher Drug Discovery Resource Center, The Rockefeller University, New York, NY, USA.
Chloe LarsonFisher Drug Discovery Resource Center, The Rockefeller University, New York, NY, USA.
Julius NitschePROTEROS Biostructures GmbH, Planegg-Martinsried, Germany.
Oleg GanichkinPROTEROS Biostructures GmbH, Planegg-Martinsried, Germany.
Hanan AlwaseemProteomics Resource Center, The Rockefeller University, New York, NY, USA.ORCID 0000-0002-4946-1436
Henrik MolinaProteomics Resource Center, The Rockefeller University, New York, NY, USA.
Stefan SteinbacherPROTEROS Biostructures GmbH, Planegg-Martinsried, Germany.
J Fraser GlickmanFisher Drug Discovery Resource Center, The Rockefeller University, New York, NY, USA.ORCID 0000-0002-6706-4039
David S PerlinCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.ORCID 0000-0002-1268-5524
Charles M RiceLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.ORCID 0000-0003-3087-8079
Peter T MeinkeSanders Tri-Institutional Therapeutics Discovery Institute, The Rockefeller University, New York, NY, USA.ORCID 0000-0002-7548-6215
Thomas TuschlLaboratory for RNA Molecular Biology, The Rockefeller University, New York, NY, USA. ttuschl@rockefeller.edu.ORCID 0000-0002-6483-5678
Funding
Virology CoreU19AI171401 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI David S Perlin, Charles M Rice · 2022 to 2026
$92.9MNIAID NIH HHS U19 AI171401
Abstract
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Indexed as
Antiviral AgentsCOVID-19 Drug TreatmentEnzyme InhibitorsExoribonucleasesMethyltransferasesRNA CapsSARS-CoV-2Viral Nonstructural ProteinsAnimalsCOVID-19Disease Models, AnimalFemaleHigh-Throughput Screening AssaysHumansMaleMiceAntiviral AgentsEnzyme InhibitorsExoribonucleasesMethyltransferasesNSP14 protein, SARS-CoV-2RNA CapsSmall Molecule LibrariesViral Nonstructural Proteins
Identifiers
PMID
39663451What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.